Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Merck China CEO Michel Vounatsos And Emerging Markets R&D Senior VP RuiPing Dong On Provincial Management: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Merck & Co. Inc. CEO Kenneth Frazier was the keynote speaker at the China Healthcare Investment Conference in Beijing March 23, stressing that his trip highlighted the place the Chinese market holds for the company's growth. After the conference, Merck, Sharpe and Dohme China President Michel Vounatsos and Merck Research Laboratory Senior VP for Emerging Markets RuiPing Dong spoke with PharmAsia News about navigating China's provincial markets and fitting China into a global R&D strategy.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Tags:
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC077715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By